The Human Molecular Genetics Group published in the journal "Cancers" a paper entitled „Exploratory Analysis of Molecular Subtypes in Early-Stage Osteosarcoma: Identifying Resistance and Optimizing Therapy“. 

New molecular subtypes have been discovered in osteosarcoma, an aggressive bone cancer that mostly affects young people. By analyzing tumors from over 100 patients, researchers identified three unique subtypes, each with different biological features and drug responses. One of the groups showed the worst prognosis and resistance to common chemotherapy drugs. However, lab tests revealed that hesperidin, a natural compound found in citrus fruits, can reduce cancer cell growth in this subtype and make chemotherapy drugs like doxorubicin more effective. This research highlights the potential for personalized treatments in osteosarcoma and suggests hesperidin could be a powerful new ally in fighting this tough cancer. 

This research is part of the dissertation of Luka Bojić, who is doing his PhD in IMGGE under the mentorship of Dr. Milena Milivojević. This publication resulted from the project BioEngineered Tumor coordinated by the Faculty of Technology and Metallurgy, University of Belgrade and funded within the PRISMA program by the Science Fund of the Republic of Serbia.